Search hospitals > California > Duarte

City of Hope Comprehensive Cancer Center

Claim this profile
Duarte, California 91010
Global Leader in Cancer
Global Leader in Lung Cancer
Conducts research for Breast Cancer
Conducts research for Lymphoma
Conducts research for Solid Tumors
2114 reported clinical trials
157 medical researchers
Photo of City of Hope Comprehensive Cancer Center in DuartePhoto of City of Hope Comprehensive Cancer Center in DuartePhoto of City of Hope Comprehensive Cancer Center in Duarte

Summary

City of Hope Comprehensive Cancer Center is a medical facility located in Duarte, California. This center is recognized for care of Cancer, Lung Cancer, Breast Cancer, Lymphoma, Solid Tumors and other specialties. City of Hope Comprehensive Cancer Center is involved with conducting 2,114 clinical trials across 1,159 conditions. There are 157 research doctors associated with this hospital, such as Daneng Li, MD, Anna Pawlowska, MD, Mark Agulnik, and Vincent Chung, MD.

Area of expertise

1Cancer
Global Leader
City of Hope Comprehensive Cancer Center has run 378 trials for Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage II
2Lung Cancer
Global Leader
City of Hope Comprehensive Cancer Center has run 266 trials for Lung Cancer. Some of their research focus areas include:
Stage IV
Stage III
EGFR positive

Top PIs

Clinical Trials running at City of Hope Comprehensive Cancer Center

Prostate Cancer
Skin Cancer
Breast Cancer
Lung Cancer
Breast cancer
Kidney Cancer
Ovarian Cancer
Cancer
Pancreatic Cancer
Multiple Myeloma
Image of trial facility.

Docetaxel + Hormone Therapy

for Prostate Cancer

This study is being done to answer the following question: can the chance of prostate cancer growing or spreading be lowered by adding a drug to the usual combination of drugs? This study would like to find out if this approach is better or worse than the usual approach for prostate cancer. The usual approach for patients who are not in a study is hormone treatment with Androgen Deprivation Therapy (ADT) and Androgen-Receptor Pathway Inhibitor (ARPI).
Recruiting2 awards Phase 35 criteria
Image of trial facility.

Ifinatamab Deruxtecan

for Prostate Cancer

Researchers are looking for new ways to treat metastatic castration-resistant prostate cancer (mCRPC). Researchers have designed a study medicine called ifinatamab deruxtecan (also called I-DXd or MK-2400) to treat mCRPC. The goal of this study is to learn if people who receive I-DXd live longer overall and live longer without the cancer growing or spreading than people who receive chemotherapy,
Recruiting2 awards Phase 32 criteria
Image of trial facility.

Apalutamide + Targeted Radiation

for Prostate Cancer

This phase III trial tests two questions by two separate comparisons of therapies. The first question is whether enhanced therapy (apalutamide in combination with abiraterone + prednisone) added to standard of care (prostate radiation therapy and short term androgen deprivation) is more effective compared to standard of care alone in patients with prostate cancer who experience biochemical recurrence (a rise in the blood level of prostate specific antigen \[PSA\] after surgical removal of the prostate cancer). A second question tests treatment in patients with biochemical recurrence who show prostate cancer spreading outside the pelvis (metastasis) by positron emission tomography (PET) imaging. In these patients, the benefit of adding metastasis-directed radiation to enhanced therapy (apalutamide in combination with abiraterone + prednisone) is tested. Diagnostic procedures, such as PET, may help doctors look for cancer that has spread to the pelvis. Androgens are hormones that may cause the growth of prostate cancer cells. Apalutamide may help fight prostate cancer by blocking the use of androgens by the tumor cells. Metastasis-directed targeted radiation therapy uses high energy rays to kill tumor cells and shrink tumors that have spread. This trial may help doctors determine if using PET results to deliver more tailored treatment (i.e., adding apalutamide, with or without targeted radiation therapy, to standard of care treatment) works better than standard of care treatment alone in patients with biochemical recurrence of prostate cancer.
Recruiting2 awards Phase 3

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at City of Hope Comprehensive Cancer Center?
Where is City of Hope Comprehensive Cancer Center located?
Who should I call to ask about financial aid or insurance network?
What insurance does City of Hope Comprehensive Cancer Center accept?
What awards or recognition has City of Hope Comprehensive Cancer Center received?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security